Details of the Drug

General Information of Drug (ID: DMBR01X)

Drug Name

Brilinta

Synonyms

Ticagrelor; 274693-27-5; Brilique; AZD-6140; AZD6140; AZD 6140; AR-C126532XX; UNII-GLH0314RVC; [14C]-Ticagrelor; GLH0314RVC; CHEBI:68558; (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-DIFLUOROPHENYL)CYCLOPROPYL]AMINO]-5-(PROPYLTHIO)-3H-1,2,3-TRIAZOLO[4,5-D]PYRIMIDIN-3-YL]-5-(2-HYDROXYETHOXY)-1,2-CYCLOPENTANEDIOL; (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; Brilique; AR-C126532; Ticagrelor (USAN/INN); Brilinta/Brilique

Indication

Disease Entry	ICD 11	Status	REF
Acute coronary syndrome	BA41	Approved	[1]
Thrombosis	DB61-GB90	Approved	[2]
Arterial thrombosis	DB61-DD30	Phase 3	[3]
Myocardial infarction	BA41-BA43	Phase 3	[3]
Peripheral vascular disease	BD4Z	Investigative	[4]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

522.6

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 6675 mcgh/L [5]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 923 mcg/L [5]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.5 h [5]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [6]
Bioavailability: The bioavailability of drug is 36% [5]
Clearance: The renal clearance of drug is 0.00584 L/h [7]
Elimination: A radiolabelled dose of ticagrelor is 57.8% recovered in feces and 26.5% recovered in urine [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 8 hours [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.002% [8]
Vd: The volume of distribution (Vd) of drug is 88 L [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Acute coronary syndrome	rs61361928	UGT2B7	OT2Q71VQ	[9]
Acute coronary syndrome	rs188845491	CYP3A5	OTSXFBXB	[9]
Acute coronary syndrome	rs147642358	ARPC1A	OTAEEXGQ	[9]
Acute coronary syndrome	rs117038461	GATS	OTDYE3XK	[9]
Peripheral sensory neuropathy	rs4141404	LIMK2	OTRJD7VZ	[10]
Peripheral sensory neuropathy	rs3892315	AIPL1	OT4VBD78	[11]
Peripheral sensory neuropathy	rs3181157	CD9	OT2184XU	[10]
Peripheral sensory neuropathy	rs275456	PAPD7	OT0G3KR0	[10]
Peripheral sensory neuropathy	rs17348202	EPHA4	OT3AMK0C	[10]
-----------


⏷ Show the Full List of 9 ADR Information of This Drug

Chemical Identifiers

Formula: C23H28F2N6O4S
IUPAC Name: (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Canonical SMILES: CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4C5=CC(=C(C=C5)F)F
InChI: InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
InChIKey: OEKWJQXRCDYSHL-FNOIDJSQSA-N

Cross-matching ID

PubChem CID: 9871419
ChEBI ID: CHEBI:68558
CAS Number: 274693-27-5
DrugBank ID: DB08816
TTD ID: D0WF7L
VARIDT ID: DR00077
INTEDE ID: DR1591
ACDINA ID: D00674

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2Y purinoceptor 12 (P2RY12)	TTZ1DT0	P2Y12_HUMAN	Antagonist	[12]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[14]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Actin-related protein 2/3 complex subunit 1A (ARPC1A)	OTAEEXGQ	ARC1A_HUMAN	Drug Response	[9]
Aryl-hydrocarbon-interacting protein-like 1 (AIPL1)	OT4VBD78	AIPL1_HUMAN	Drug Response	[11]
CD9 antigen (CD9)	OT2184XU	CD9_HUMAN	Drug Response	[10]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Drug Response	[9]
Ephrin type-A receptor 4 (EPHA4)	OT3AMK0C	EPHA4_HUMAN	Drug Response	[10]
LIM domain kinase 2 (LIMK2)	OTRJD7VZ	LIMK2_HUMAN	Drug Response	[10]
Putative protein CASTOR3P (GATS)	OTDYE3XK	CAST3_HUMAN	Drug Response	[9]
Terminal nucleotidyltransferase 4A (TENT4A)	OT0G3KR0	PAPD7_HUMAN	Drug Response	[10]
UDP-glucuronosyltransferase 2B7	OT2Q71VQ	UD2B7_HUMAN	Drug Response	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Brilinta (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Brilinta caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[15]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Brilinta caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Arn-509	DMT81LZ	Major	Increased metabolism of Brilinta caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[16]
Gilteritinib	DMTI0ZO	Moderate	Decreased metabolism of Brilinta caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[17]
Oliceridine	DM6MDCF	Moderate	Decreased metabolism of Brilinta caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[17]
Ivabradine	DM0L594	Moderate	Decreased metabolism of Brilinta caused by Ivabradine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[17]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Brilinta caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[19]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Brilinta caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[15]
LY2835219	DM93VBZ	Moderate	Decreased metabolism of Brilinta caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Tucatinib	DMBESUA	Major	Decreased metabolism of Brilinta caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[18]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Brilinta caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[17]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Brilinta caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[21]
PF-04449913	DMSB068	Moderate	Decreased metabolism of Brilinta caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[22]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Brilinta and Levomilnacipran.	Chronic pain [MG30]	[23]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Brilinta due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[18]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Brilinta and Regorafenib.	Colorectal cancer [2B91]	[17]
Intedanib	DMSTA36	Moderate	Increased risk of bleeding by the combination of Brilinta and Intedanib.	Colorectal cancer [2B91]	[24]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Brilinta caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[17]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Brilinta caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[25]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Brilinta caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[17]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Brilinta caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[17]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Brilinta and Vortioxetine.	Depression [6A70-6A7Z]	[23]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Brilinta caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[26]
Apigenin	DMI3491	Minor	Increased risk of bleeding by the combination of Brilinta and Apigenin.	Discovery agent [N.A.]	[27]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Brilinta caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Brilinta caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Bay 80-6946	DMLOS5R	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by Bay 80-6946.	Follicular lymphoma [2A80]	[28]
Tazemetostat	DMWP1BH	Moderate	Decreased metabolism of Brilinta caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[29]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Brilinta caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[30]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Brilinta and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[17]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Brilinta caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[18]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[31]
MK-1439	DM215WE	Minor	Decreased metabolism of Brilinta caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Brilinta caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Brilinta caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[33]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[34]
Aliskiren	DM1BV7W	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by Aliskiren.	Hypertension [BA00-BA04]	[15]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Brilinta caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[15]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Brilinta caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[17]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Brilinta caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[18]
Naloxegol	DML0B41	Minor	Decreased clearance of Brilinta due to the transporter inhibition by Naloxegol.	Large intestine motility disorder [DB32]	[35]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Brilinta caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[17]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Brilinta caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[15]
Ceritinib	DMB920Z	Major	Decreased metabolism of Brilinta caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[18]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Brilinta caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[36]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Brilinta caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[15]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Brilinta caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[37]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Brilinta caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[38]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[39]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Brilinta caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[17]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Brilinta and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[40]
Idelalisib	DM602WT	Major	Decreased metabolism of Brilinta caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[18]
GDC-0199	DMH0QKA	Major	Decreased clearance of Brilinta due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[18]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Brilinta caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[17]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Brilinta and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[41]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Brilinta and Ibrutinib.	Mature B-cell lymphoma [2A85]	[42]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Brilinta and Ponatinib.	Mature B-cell lymphoma [2A85]	[43]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[18]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Brilinta caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[15]
LGX818	DMNQXV8	Moderate	Increased metabolism of Brilinta caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[44]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Brilinta caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[17]
Ubrogepant	DM749I3	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by Ubrogepant.	Migraine [8A80]	[45]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[46]
Fedratinib	DM4ZBK6	Moderate	Increased risk of bleeding by the combination of Brilinta and Fedratinib.	Myeloproliferative neoplasm [2A20]	[17]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Brilinta and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[17]
Vorapaxar	DMA16BR	Moderate	Increased risk of bleeding by the combination of Brilinta and Vorapaxar.	Myocardial infarction [BA41-BA43]	[17]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[47]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Brilinta caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[17]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Brilinta caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[48]
S-297995	DM26IH8	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by S-297995.	Opioid use disorder [6C43]	[17]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Brilinta caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[49]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Brilinta caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[50]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Brilinta and MK-4827.	Ovarian cancer [2C73]	[17]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Brilinta caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[51]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Brilinta caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[52]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Brilinta and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[17]
Enzalutamide	DMGL19D	Major	Increased metabolism of Brilinta caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[16]
Relugolix	DMK7IWL	Major	Decreased clearance of Brilinta due to the transporter inhibition by Relugolix.	Prostate cancer [2C82]	[53]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Brilinta caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[17]
LDE225	DMM9F25	Moderate	Decreased metabolism of Brilinta caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[54]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Brilinta caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[17]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Brilinta caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
LEE011	DMMX75K	Moderate	Decreased metabolism of Brilinta caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Curcumin	DMQPH29	Minor	Increased risk of bleeding by the combination of Brilinta and Curcumin.	Solid tumour/cancer [2A00-2F9Z]	[55]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Brilinta caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[56]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Brilinta due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[50]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Brilinta and Cabozantinib.	Thyroid cancer [2D10]	[57]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Brilinta caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[15]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Brilinta and Betrixaban.	Venous thromboembolism [BD72]	[58]
-----------


⏷ Show the Full List of 90 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Brushite	E00392	104805	Diluent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ticagrelor 60 mg tablet	60 mg	Oral Tablet	Oral
Ticagrelor 90 mg tablet	90 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Ticagrelor-Induced Syncope/Bradyarrhythmia. Cureus. 2021 Jan 23;13(1):e12874.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1765).
3	ClinicalTrials.gov (NCT01732822) A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease. U.S. National Institutes of Health.
4	Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs. 2022 Aug;82(12):1287-1302.
5	FDA Approved Drug Products: Brilinta Ticagrelor Oral Tablets
6	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
7	Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21. doi: 10.1124/dmd.110.032250. Epub 2010 Jun 15.
8	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015 Aug 1;36(29):1901-12.
10	Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet. 2013 Sep;50(9):599-605. doi: 10.1136/jmedgenet-2012-101466. Epub 2013 Jun 17.
11	Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. Clin Cancer Res. 2015 Oct 1;21(19):4337-46. doi: 10.1158/1078-0432.CCR-15-0133. Epub 2015 May 26.
12	Clinical pipeline report, company report or official report of AstraZeneca (2009).
13	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
14	Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21.
15	Canadian Pharmacists Association.
16	Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	Cerner Multum, Inc. "Australian Product Information.".
19	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
20	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
21	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
22	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
23	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
24	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
25	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
26	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
27	Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
28	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
29	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
30	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
31	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
32	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
33	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
34	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
35	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
36	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
37	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
38	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
39	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
40	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
41	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
42	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
43	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
44	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
45	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
46	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
47	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
48	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
49	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
50	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
51	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
52	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
53	Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
54	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
55	Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
56	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
57	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
58	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.